Literature DB >> 11925137

Muscarinic receptors in cell lines from ovarian carcinoma: negative correlation with survival of patients.

M Oppitz1, V Möbus, S Brock, U Drews.   

Abstract

OBJECTIVES: Tumor cells are similar in many respects to embryonic cells, indicating that embryonic genes are reactivated during malignant growth. In previous studies, we observed muscarinic acetylcholine receptors, which are expressed in embryonic cells during morphogenesis and are also found in human melanomas and melanoma cell lines. We determined the presence of muscarinic receptors in a collection of ovarian tumor cell lines for which clinical data were available.
METHODS: Muscarinic receptor status of 39 cell lines derived from 34 patients was determined by Western blotting.
RESULTS: Twenty-three cell lines were receptor positive, and 16, receptor negative. Kaplan-Meier analysis of receptor status of the tumor cell lines and survival time of patients from which the cell lines were established showed that expression of muscarinic receptors was associated with a reduced probability (P = 0.025) of survival: This is within the range of other established prognostic factors reported in the literature.
CONCLUSIONS: A large percentage of ovarian tumor cell lines express muscarinic receptors. Muscarinic receptor expression is an embryonic trait and is correlated with reduced survival of patients. The results from this study provide further evidence of the involvement of muscarinic receptors in the progression of malignant carcinomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11925137     DOI: 10.1006/gyno.2002.6597

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  16 in total

Review 1.  Muscarinic receptors and ligands in cancer.

Authors:  Nirish Shah; Sandeep Khurana; Kunrong Cheng; Jean-Pierre Raufman
Journal:  Am J Physiol Cell Physiol       Date:  2008-11-26       Impact factor: 4.249

Review 2.  GPCRs and cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

3.  High expression of M3 muscarinic acetylcholine receptor is a novel biomarker of poor prognostic in patients with non-small cell lung cancer.

Authors:  Jun Wu; Jinxu Zhou; Lei Yao; Yaoguo Lang; Yingnan Liang; Lantao Chen; Jinfeng Zhang; Fengjiao Wang; Yanbo Wang; He Chen; Jianqun Ma
Journal:  Tumour Biol       Date:  2013-07-10

Review 4.  Muscarinic receptor agonists and antagonists: effects on cancer.

Authors:  Eliot R Spindel
Journal:  Handb Exp Pharmacol       Date:  2012

Review 5.  New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.

Authors:  Nigel H Greig; Marcella Reale; Ada M Tata
Journal:  Recent Pat CNS Drug Discov       Date:  2013-08

6.  Aclidinium inhibits proliferation and metastasis of ovarian cancer SKOV3 cells via downregulating PI3K/AKT/mTOR signaling pathway.

Authors:  Juan Qiao; Wei-Jing Wang; Yuan Zhang
Journal:  Oncol Lett       Date:  2018-09-19       Impact factor: 2.967

7.  Cholinergic receptor pathways involved in apoptosis, cell proliferation and neuronal differentiation.

Authors:  Rodrigo R Resende; Avishek Adhikari
Journal:  Cell Commun Signal       Date:  2009-08-27       Impact factor: 5.712

8.  A novel muscarinic antagonist R2HBJJ inhibits non-small cell lung cancer cell growth and arrests the cell cycle in G0/G1.

Authors:  Nan Hua; Xiaoli Wei; Xiaoyan Liu; Xiaoyun Ma; Xinhua He; Rengong Zhuo; Zhe Zhao; Liyun Wang; Haitao Yan; Bohua Zhong; Jianquan Zheng
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

9.  M2muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells.

Authors:  Luca Pacini; Elena De Falco; Maria Di Bari; Andrea Coccia; Camilla Siciliano; Donatella Ponti; Antonio Luigi Pastore; Vincenzo Petrozza; Antonio Carbone; Ada Maria Tata; Antonella Calogero
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

10.  M2 receptor activation inhibits cell cycle progression and survival in human glioblastoma cells.

Authors:  Michela Ferretti; Cinzia Fabbiano; Maria Di Bari; Claudia Conte; Emilia Castigli; Miriam Sciaccaluga; Donatella Ponti; Paola Ruggieri; Antonino Raco; Ruggero Ricordy; Antonella Calogero; Ada Maria Tata
Journal:  J Cell Mol Med       Date:  2013-03-14       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.